Fumitake Kai

537 total citations
19 papers, 436 citations indexed

About

Fumitake Kai is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Fumitake Kai has authored 19 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Fumitake Kai's work include Renal cell carcinoma treatment (8 papers), Cancer-related Molecular Pathways (7 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Fumitake Kai is often cited by papers focused on Renal cell carcinoma treatment (8 papers), Cancer-related Molecular Pathways (7 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Fumitake Kai collaborates with scholars based in Japan and United States. Fumitake Kai's co-authors include Robert D. Kendig, Kazushi Inoue, Dejan Maglic, Pankaj Taneja, Takayuki Sugiyama, Donna P. Frazier, Sinan Zhu, Mark C. Willingham, Hiroshi Furuse and Elizabeth A. Fry and has published in prestigious journals such as Cancer Research, Oncogene and International Journal of Molecular Sciences.

In The Last Decade

Fumitake Kai

18 papers receiving 428 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fumitake Kai Japan 10 231 220 117 100 58 19 436
Miklós Gulyás Sweden 12 203 0.9× 141 0.6× 196 1.7× 66 0.7× 62 1.1× 28 509
Zhanhuai Wang China 12 243 1.1× 231 1.1× 68 0.6× 170 1.7× 59 1.0× 24 501
Zenobia D’Costa United Kingdom 12 405 1.8× 268 1.2× 84 0.7× 115 1.1× 48 0.8× 14 655
Leili Saeednejad Zanjani Iran 13 201 0.9× 273 1.2× 102 0.9× 114 1.1× 50 0.9× 37 497
Yoshikuni Yonenaga Japan 8 133 0.6× 227 1.0× 68 0.6× 172 1.7× 62 1.1× 26 419
Kristopher A. Lofgren United States 9 198 0.9× 278 1.3× 77 0.7× 88 0.9× 21 0.4× 20 451
Devang Panchal Canada 5 303 1.3× 235 1.1× 108 0.9× 190 1.9× 24 0.4× 7 511
Brunella Costanza Belgium 8 197 0.9× 279 1.3× 56 0.5× 156 1.6× 32 0.6× 9 470
Maximilian Schnurr Germany 4 274 1.2× 184 0.8× 41 0.4× 102 1.0× 49 0.8× 4 470
Edina Bugyik Hungary 13 164 0.7× 186 0.8× 89 0.8× 104 1.0× 78 1.3× 23 450

Countries citing papers authored by Fumitake Kai

Since Specialization
Citations

This map shows the geographic impact of Fumitake Kai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumitake Kai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumitake Kai more than expected).

Fields of papers citing papers by Fumitake Kai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fumitake Kai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumitake Kai. The network helps show where Fumitake Kai may publish in the future.

Co-authorship network of co-authors of Fumitake Kai

This figure shows the co-authorship network connecting the top 25 collaborators of Fumitake Kai. A scholar is included among the top collaborators of Fumitake Kai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fumitake Kai. Fumitake Kai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Fry, Elizabeth A., et al.. (2020). Survival of Lung Cancer Patients Dependent on the LOH Status for DMP1, ARF, and p53. International Journal of Molecular Sciences. 21(21). 7971–7971. 2 indexed citations
2.
Kendig, Robert D., Fumitake Kai, Elizabeth A. Fry, & Kazushi Inoue. (2017). Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α. Cancer Investigation. 35(5). 301–312. 9 indexed citations
3.
Inoue, Keiji, Satoshi Anai, Kiyohide Fujimoto, et al.. (2015). Oral 5-aminolevulinic acid mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A randomized, double-blind, multicentre phase II/III study. Photodiagnosis and Photodynamic Therapy. 12(2). 193–200. 67 indexed citations
4.
Takayama, Tatsuya, Hiroshi Furuse, Fumitake Kai, Takayuki Sugiyama, & Seiichiro Ozono. (2013). Temsirolimus controlled metastatic advanced renal cell carcinoma for over 4 years: a case study. Medical Oncology. 30(2). 563–563. 3 indexed citations
5.
Takayama, Tatsuya, et al.. (2013). Axitinib Controlled Metastatic Renal Cell Carcinoma for 5 Years. Japanese Journal of Clinical Oncology. 43(7). 747–751. 3 indexed citations
6.
Tamura, Keita, Hiroshi Furuse, Takayuki Sugiyama, et al.. (2013). BILATERAL ADRENAL HEMORRHAGE DUE TO ADRENAL METASTASIS OF LUNG CANCER. The Japanese Journal of Urology. 104(1). 17–21. 2 indexed citations
7.
Frazier, Donna P., Robert D. Kendig, Fumitake Kai, et al.. (2012). Dmp1 Physically Interacts with p53 and Positively Regulates p53′s Stability, Nuclear Localization, and Function. Cancer Research. 72(7). 1740–1750. 34 indexed citations
8.
Maglic, Dejan, Elizabeth A. Fry, Pankaj Taneja, et al.. (2012). Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. Oncogene. 32(35). 4120–4129. 30 indexed citations
9.
Takayama, Tatsuya, Takashi Sugiyama, Fumitake Kai, et al.. (2011). Should Ipsilateral Solitary Adrenal Involvement in Renal Cell Carcinoma be Staged as M1?. Japanese Journal of Clinical Oncology. 41(6). 792–796.
10.
Takayama, Tatsuya, Takayuki Sugiyama, Fumitake Kai, et al.. (2011). Characteristics of aggressive variants in T1a renal cell carcinoma. Journal of Cancer Research and Clinical Oncology. 137(11). 1653–1659. 12 indexed citations
11.
Maglic, Dejan, et al.. (2011). Abstract 3076: MEKK1 is a novel modulator of the Arf-p53 pathway via Dmp1 phosphorylation. Cancer Research. 71(8_Supplement). 3076–3076. 1 indexed citations
12.
Taneja, Pankaj, Dejan Maglic, Fumitake Kai, et al.. (2010). Critical Roles of DMP1 in Human Epidermal Growth Factor Receptor 2/neu-Arf-p53 Signaling and Breast Cancer Development. Cancer Research. 70(22). 9084–9094. 33 indexed citations
13.
Kai, Fumitake, et al.. (2010). Natural history of renal cell carcinoma: a case with 18 years follow-up. Clinical and Experimental Nephrology. 15(2). 312–315. 1 indexed citations
14.
Taneja, Pankaj, Dejan Maglic, Fumitake Kai, et al.. (2010). Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clinical Medicine Insights Oncology. 4. 15–34. 125 indexed citations
15.
Taneja, Pankaj, Donna P. Frazier, Robert D. Kendig, et al.. (2009). MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Review of Molecular Diagnostics. 9(5). 423–440. 56 indexed citations
16.
Liu, Hongming, Tatsuya Takayama, Hiroshi Ogawa, et al.. (2009). Impact of Thymidine Phosphorylase-Expressing Macrophages for Surgical Margin in Partial Nephrectomy. Urologia Internationalis. 82(4). 388–393. 2 indexed citations
17.
Mallakin, Ali, Takayuki Sugiyama, Fumitake Kai, et al.. (2009). The Arf‐inducing transcription factor Dmp1 encodes a transcriptional activator of amphiregulin, thrombospondin‐1, JunB and Egr1. International Journal of Cancer. 126(6). 1403–1416. 33 indexed citations
18.
Kai, Fumitake, Tatsuya Takayama, Takashi Sugiyama, et al.. (2009). Efficacy of Adjuvant Interferon-alpha Therapy Following Curative Resection in Renal Cell Carcinoma: Before the Molecular Targeting Therapy Era. Japanese Journal of Clinical Oncology. 39(5). 310–314. 3 indexed citations
19.
Takayama, Tatsuya, Soichi Mugiya, Takayuki Sugiyama, et al.. (2006). High Levels of Thymidine Phosphorylase as an Independent Prognostic Factor in Renal Cell Carcinoma. Japanese Journal of Clinical Oncology. 36(9). 564–569. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miklós Gulyás Breakdown of academic impact, for papers by Zhanhuai Wang Breakdown of academic impact, for papers by Zenobia D’Costa Breakdown of academic impact, for papers by Leili Saeednejad Zanjani Breakdown of academic impact, for papers by Yoshikuni Yonenaga Breakdown of academic impact, for papers by Kristopher A. Lofgren Breakdown of academic impact, for papers by Devang Panchal Breakdown of academic impact, for papers by Brunella Costanza Breakdown of academic impact, for papers by Maximilian Schnurr Breakdown of academic impact, for papers by Edina Bugyik
Rankless by CCL
2026